Search Result

Isoforms Recommended:	PPARδ PPARβ/δ

Results for "

Pparδ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Adenosine Receptor (1) Akt (2) ATP-binding cassette (ABC) transporters (1) Autophagy (2) Carnitine Palmitoyltransferase (CPT) (1) CDK (1) COX (4) Drug Derivative (2) Endogenous Metabolite (9) Epoxide Hydrolase (1) ERK (1) Estrogen Receptor/ERR (1) FABP (2) Fatty Acid Synthase (FASN) (1) Free Fatty Acid Receptor (3) FXR (1) Hedgehog (5) Isotope-Labeled Compounds (9) Ligands for Target Protein for PROTAC (1) NO Synthase (2) PDHK (1) PPAR (92) Prostaglandin Receptor (1) Reference Standards (9) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (12) Endocrinology (2) Inflammation/Immunology (22) Metabolic Disease (63) Neurological Disease (6)

By Targets:

17β-HSD (1)

Adenosine Receptor (1)

Akt (2)

ATP-binding cassette (ABC) transporters (1)

Autophagy (2)

Carnitine Palmitoyltransferase (CPT) (1)

CDK (1)

COX (4)

Drug Derivative (2)

Endogenous Metabolite (9)

Epoxide Hydrolase (1)

ERK (1)

Estrogen Receptor/ERR (1)

FABP (2)

Fatty Acid Synthase (FASN) (1)

Free Fatty Acid Receptor (3)

FXR (1)

Hedgehog (5)

Isotope-Labeled Compounds (9)

Ligands for Target Protein for PROTAC (1)

NO Synthase (2)

PDHK (1)

PPAR (92)

Prostaglandin Receptor (1)

Reference Standards (9)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (20)

Cardiovascular Disease (12)

Endocrinology (2)

Inflammation/Immunology (22)

Metabolic Disease (63)

Neurological Disease (6)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16578

GW9662 Maximum Cited Publications 208 Publications Verification	PPAR	Cancer
GW9662 is a potent and selective PPARγ antagonist with an IC₅₀ of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.

HY-10838

GW 501516 25+ Cited Publications GW 1516; GSK-516	PPAR Autophagy	Metabolic Disease Cancer
GW 501516 (GW 1516) is a *PPARδ* agonist with an EC₅₀ of 1.1 nM .

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent PPARα agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-16995

Pirinixic acid 30+ Cited Publications Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-B0637

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-19522

Seladelpar 1 Publications Verification MBX-8025; RWJ-800025	PPAR	Metabolic Disease
Seladelpar (MBX-8025) is an orally active, potent and specific *PPARδ* agonist with an EC₅₀ of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-13928

GW0742 15+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and *PPARδ* agonist, with an IC₅₀ of 1 nM for human *PPARδ* in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human *PPARδ, PPARα, and PPAR*γ, respectively.

HY-15577

GSK3787 15+ Cited Publications	PPAR	Cancer
GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC₅₀ of 6.6.

HY-106266

Chiglitazar 1 Publications Verification Carfloglitazar	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 2 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	PPAR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent *PPARδ* agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-113081

1-Methyladenosine 4 Publications Verification	Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of *PPARδ* expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-B0760

Fenofibric acid 3 Publications Verification FNF acid	PPAR COX	Metabolic Disease
Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-112813

TUG-1375 4 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-20019

L-165041 2 Publications Verification	PPAR	Metabolic Disease
L-165041 is a cell permeable *PPARδ* agonist, with K_is of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

HY-14817

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

HY-114263

NXT629 4 Publications Verification	PPAR	Cancer
NXT629 is a potent, selective, and competitive *PPAR-α* antagonist, with an IC₅₀ of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC₅₀s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .

HY-U00425

PROTAC ERRα ligand 1	Ligands for Target Protein for PROTAC Estrogen Receptor/ERR	Metabolic Disease Cancer
PROTAC ERRα ligand 1 is a PROTAC target protein ligand. PROTAC ERRα ligand 1 is an orally active ERRα inverse agonist with IC₅₀ values of 0.6 μM for ERRα. PROTAC ERRα ligand 1 shows no significant activity against a panel of other nuclear receptors, including ERα ^c, ERRγ, ERβ, PPARα, PPARγ, PPARδ, and RXRα. PROTAC ERRα ligand 1 can provide enhanced insulin sensitivity in vivo. PROTAC ERRα ligand 1 can be used for metabolic diseases research, such as type 2 diabetes and obesity .

HY-134377

Bocidelpar ASP0367; MA-0211	PPAR	Metabolic Disease
Bocidelpar (ASP0367; MA-0211) is a selective, orally active *PPARδ* modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) .

HY-112597A

Mavodelpar REN001; HPP593	PPAR	Inflammation/Immunology
Mavodelpar (REN001) is a selective *PPARδ* agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD) . Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106278

GW 590735 1 Publications Verification	PPAR	Metabolic Disease
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-19522A

Seladelpar sodium 1 Publications Verification MBX-8025 sodium; RWJ-800025 sodium	PPAR	Metabolic Disease Inflammation/Immunology
Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific *PPARδ* agonist with an EC₅₀ of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .

HY-113081R

1-Methyladenosine (Standard)	Reference Standards Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of *PPARδ* expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .

HY-B0760S

Fenofibric acid-d6	PPAR COX	Metabolic Disease
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-168376

9(10)-Nitrooleate 9(10)-Nitrated oleic acid	PPAR ERK Akt NO Synthase	Metabolic Disease Inflammation/Immunology
9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases .

HY-168049

ZLY06	PPAR Akt	Metabolic Disease
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC₅₀=341 nM; PPAR γ: EC₅₀=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .

HY-119966

CCT036477	Wnt β-catenin PPAR CDK	Cancer
CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .

HY-B0760R

Fenofibric acid (Standard) 3 Publications Verification FNF acid (Standard)	Reference Standards PPAR COX	Metabolic Disease
Fenofibric acid (Standard) is the analytical standard of Fenofibric acid. This product is intended for research and analytical applications. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent **PPARα/PPARδ** dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-130120

HWL-088	Free Fatty Acid Receptor PPAR	Metabolic Disease
HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC₅₀ of 18.9 nM) with moderate *PPARδ* activity (EC₅₀ of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .

HY-114739

MA-0204	PPAR	Metabolic Disease
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC₅₀s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) .

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-10838R

GW 501516 (Standard) GW 1516 (Standard); GSK-516 (Standard)	Reference Standards PPAR Autophagy	Metabolic Disease Cancer
GW 501516 (Standard) is the analytical standard of GW 501516. This product is intended for research and analytical applications. GW 501516 (GW 1516) is a PPARδ agonist with an EC50 of 1.1 nM .

HY-113081S1

1-Methyladenosine-d3 hydriodide	Isotope-Labeled Compounds Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine-d3 hydriodide is the deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-168336

E0924G	PPAR	Metabolic Disease
E0924G is an orally active activator for *PPARδ* with EC₅₀ of 2.82 μM. E0924G promotes the upregulation of osteoprotegerin (OPG) with an EC₅₀ of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibites F-actin ring formation in RAW264.7 macrophages. E0924G regulates the bone density and bone loss in ovariectomized (OVX) and age-related osteoporosis models .

HY-19522C

Seladelpar (lysine dihydrate) 1 Publications Verification MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)	PPAR	Metabolic Disease
Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent *PPAR-δ, with EC₅₀* of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .

HY-17633

Fonadelpar NPS-005; SJP-0035	PPAR	Neurological Disease
Fonadelpar is a *PPARδ* agonist, used in the research of neuroparalytic keratopathy.

HY-111068

KD-3010	PPAR	Metabolic Disease
KD-3010 is a potent, orally active, and selective *PPARδ* agonist.

HY-143862

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of *Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ* agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

HY-120596

PPARδ/γ agonist 1 sodium	PPAR	Neurological Disease
PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist. PPARδ/γ agonist 1 sodium can be used for the research of Alzheimer’s disease .

HY-Y1624

1,1'-(Azodicarbonyl)-dipiperidine ADDP; SR 4077	Free Fatty Acid Receptor PPAR	Metabolic Disease
1,1'-(Azodicarbonyl)-dipiperidine (ADDP) can be used in the condensation reaction of alcohols with acidic compounds. 1,1'-(Azodicarbonyl)-dipiperidine can also be used in the synthesis of GPR120 agonists with antidiabetic activity, as well as the synthesis of triple agonists for PPARα, PPARγ, and *PPARδ*. 1,1'-(Azodicarbonyl)-dipiperidine can be used in metabolic disease research .

HY-113081AS

1-Methyladenosine-d3 hydrochloride	Isotope-Labeled Compounds Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of *PPARδ* expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-107901

Pparδ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
Pparδ agonist 1 is a *PPAR-δ* agonist, with an EC₅₀ of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.

HY-147757

PPARγ/δ modulator 1	PPAR	Metabolic Disease
PPARγ/δ modulator 1 (compound 3e) is a potent *PPAR* modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with K_i values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC₅₀ of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .

HY-178332

*sEH/PPARδ* modulator 1**	Epoxide Hydrolase PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
sEH/PPARδ modulator 1 is a sEH/PPARδ dual modulator. sEH/PPARδ modulator 1 can inhibit sEH with an IC₅₀ of 0.46 μM and activate PPARδ with an EC₅₀ of 0.12 μM. sEH/PPARδ modulator 1 can be used for the researches of inflammation, metabolic and cardiovascular disease .

HY-13928R

GW0742 (Standard) GW610742 (Standard)	PPAR Reference Standards	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 (Standard) is the analytical standard of GW0742. This product is intended for research and analytical applications. GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-116257

GSK-7227	PPAR PDHK Carnitine Palmitoyltransferase (CPT)	Others
GSK-7227 (compound 32) is a PPARδ partial agonist with the activity of regulating the expression of related genes. GSK-7227 has partial agonist effects on PPARδ target genes CPT1a and PDK4 in skeletal muscle cells.

HY-143863

PPARδ agonist 8	PPAR	Metabolic Disease
Pparδ agonist 8 is a potent agonist of *Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ* agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .

HY-120255A

17(S)-HDHA	PPAR	Metabolic Disease
17(S)-HDHA is a pro-resolving mediator (SPM). 17(S)-HDHA slightly activats PPARγ, PPARα and *PPARδ* .

HY-106266B

Chiglitazar sodium 1 Publications Verification Carfloglitazar sodium	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-17618A

Rac-Pemafibrate Rac-K13675	PPAR	Inflammation/Immunology
Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC₅₀s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 2 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent *PPARδ* agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-113081

1-Methyladenosine 4 Publications Verification	Alkaloids Microorganisms Immune System Disorder Classification of Application Fields Disease markers Other Diseases Endogenous metabolite Disease Research Fields Cancer Source Classification	Endogenous Metabolite PPAR Hedgehog
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of *PPARδ* expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-113081R

1-Methyladenosine (Standard)	Alkaloids Structural Classification Microorganisms Immune System Disorder Disease markers Endogenous metabolite Cancer Source Classification	Reference Standards Endogenous Metabolite PPAR Hedgehog
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of *PPARδ* expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .

Cat. No.	Product Name	Chemical Structure

HY-B0760S

Fenofibric acid-d6
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-113081S1

1-Methyladenosine-d3 hydriodide

1-Methyladenosine-d3 hydriodide is the deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-113081AS

1-Methyladenosine-d3 hydrochloride

1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-16578S

GW9662-d5
GW9662-d₅ is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC₅₀ of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively .

HY-113081S

1-Methyladenosine-d3
1-Methyl Adenosine-d3 is the deuterium labeled 1-Methyladenosine. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0760S1

Fenofibric acid-13C8
Fenofibric acid- ¹³C₈ (FNF acid- ¹³C₈) is ¹³C labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-B0760S2

Fenofibric acid-d4
Fenofibric acid-d₄ (FNF acid-d₄) is deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks